ShareSoc Growth Company Seminar (IN-PERSON EVENT), London 13 November 2025, 5pm
Featuring: Bioventix (BVXP), TheraCryf plc (TCF), and speaker Dr Arron Aatkar, Healthcare Analyst at Edison
Location: ISH Venues
229 Great Portland Street
W1W 5PN
Companies presenting
Bioventix (BVXP)
Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.
Most of Bioventix’s antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world. Bioventix makes antibodies using its SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.
Presenter:
Peter Harrison- CEO
Peter is 65 years old and has ~30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.
TheraCryf plc (TCF)
TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders (*orphan indication).
Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has industry partnerships with companies including Stalicla SA, in neurodevelopmental disorders.
Presenters:
Dr Huw Jones, CEO
Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK
Dr Helen Kuhlman, COO
Helen has over 20 years’ experience in life science beginning her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has been an active proponent of the UK biotech innovation ecosystem, leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath.
Speaker
Dr Arron Aatkar, Healthcare Analyst at Edison
Arron joined Edison’s healthcare team as an equity analyst in January 2023 and has covered over 30 companies within the sector since joining. Prior to this, he worked at GSK for four years and completed a PhD in chemical biology through the GSK/University of Strathclyde Collaborative PhD Programme. During this time, he conducted extensive research into novel therapeutic technologies, with a particular focus on covalent drug discovery, oncology, and various rare diseases. Arron also holds an integrated MSci degree in chemistry from the University of Bristol.
This seminar consists of a 25-minute presentation by each company followed by 15 minutes of questions and answers.
After the presentations there will be an hour of Networking with light buffet and wine where you will have the opportunity to engage directly with company directors and share your investing experience with fellow investors.
Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
Places are limited and will be allocated on a first come, first served.
Stockopedia will provide facts and figures on the presenting companies for attendees (don’t forget that ShareSoc subscribing members can get a special discount on Stockopedia subscription rates – see Member Offers).
Registration
To register, members should log in, then just click “SUBMIT” below.
for help on logging in or email
If you are not yet a member, please complete the registration form below and you will automatically be granted Associate membership.
